TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3552076
Drug: Continue maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue maintenance therapy for a total of 3 years
Study: 3552076
Drug: Discontinue all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinue all therapy at 8 months
Study: 25595508
Drug: Staff identification
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staff identification of treatment device
Study: 18714150
Drug: Spirulina (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (8 g/day for 16 weeks)
Study: 17361594
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (wavelength 904 nm, frequency 4000 Hz, at dose 2J per point); TENS (frequency 80 Hz, 30 minutes, pulse duration 200 micros); exercise; conventional therapy with NSAIDs (meloxicam, 15 mg per day)
Study: 17361594
Drug: Meloxicam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (15 mg per day)
Study: 11071328
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 microg daily, subcutaneously for the first 10 postoperative days)
Study: 1418029
Drug: IX 800
Normalized name: PREZCOBIX 800mg-150mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: IX 800 mg
Study: 1418029
Drug: IX 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IX 1,200 mg
Study: 31798713
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral cholecalciferol [2,000 IU per day] (experimental group)
Study: 31798713
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without supplementation (control group)
Study: 30282391
Drug: High-voltage pulsed
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-voltage pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds, followed by lidocaine and normal saline injection.
Study: 30282391
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block treatment with 1.4 mL of a mixture of dexamethasone and lidocaine after 360 seconds of sham PRF treatment, followed by 0.5 mL of normal saline.
Study: 30282391
Drug: High-voltage pulsed
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-voltage pulsed radiofrequency (PRF) treatment.
Study: 30282391
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block treatment.
Study: 20946621
Drug: Active physiotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active physiotherapy treatment (manual therapy and exercise plus education and advice)
Study: 20946621
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham ultrasound and non‐therapeutic gel)
Study: 12154207
Drug: Leflunomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (100 mg initially, then 20 mg/day)
Study: 12154207
Drug: Methotrexate (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15-20 mg/day)
Study: 7018680
Drug: Combination vinblastine-CCNU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vinblastine-CCNU
Study: 7018680
Drug: Single-agent triazinate
Normalized name: BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent triazinate
Study: 7018680
Drug: Single-agent dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent dactinomycin
Study: 24399187
Drug: Cleansing formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing formulation only (Group 1)
Study: 24399187
Drug: Cleansing solution
Normalized name: Cleansing Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing solution and moisturizing solution (Group 2)
Study: 24399187
Drug: Cleansing formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing formulation and moisturizing formulation (Group 3)
Study: 18991158
Drug: Cognitive-behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural group therapy (n=7)
Study: 15804684
Drug: Active 21‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active 21‐mg nicotine patch
Study: 15804684
Drug: Active 2‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active 2‐mg or 4-mg nicotine lozenge
Study: 15804684
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for both patch and lozenge)
Study: 12153829
Drug: WS 5570
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 5570 (300 mg t.i.d.)
Study: 2085991
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (FT) 3 g single dose
Study: 2085991
Drug: Pipemidic acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic acid (PA) 400 mg b.i.d. for seven days
Study: 343660
Drug: Fenoterol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.4 mg t.i.d.)
Study: 343660
Drug: Isoproterenol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (0.15 mg t.i.d.)
Study: 29807811
Drug: Antibiotic-impregnated nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-impregnated nasal packing
Study: 29807811
Drug: Steroid-impregnated nasal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid-impregnated nasal packing
Study: 29807811
Drug: Saline solution-impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution-impregnated nasal packing
Study: 28333952
Drug: OM-85 (3.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-85 (3.5mg daily for 9 months)
Study: 24444038
Drug: T1DM-G (HbA1c
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1DM-G (HbA1c ≤ 7.5%)
Study: 24444038
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (T1DM-G, T1DM-P, controls)
Study: 21808844
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 ml/kg orange flavored juice)
Study: 10759039
Drug: Single-session (SS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session (SS) treatment
Study: 10759039
Drug: Treatment-as-needed (TAN)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-needed (TAN)
Study: 8832303
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid with glycine (test formulation)
Study: 8832303
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid without glycine (reference formulation)
Study: 20920045
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro protamine suspension (ILPS) injected once or twice daily
Study: 20920045
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injected once daily
Study: 15804248
Drug: Oral creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral creatine (Cr) monohydrate at a dosage of 150 mg/kg body weight/day
Study: 12519334
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of ITI implants (6 weeks healing)
Study: 12519334
Drug: Conventional loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional loading of ITI implants (12 weeks healing)
Study: 7201816
Drug: Syracerin (steroid-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syracerin (steroid-free partner drug) applied at 4-13-day intervals
Study: 7201816
Drug: Interval application
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval application of topical corticoids
Study: 30548426
Drug: Carbohydrate (CHO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO; 145 g; n=9)
Study: 26719947
Drug: Immediate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prescription strategy
Study: 26719947
Drug: No prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prescription strategy
Study: 26719947
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription collection strategy
Study: 26719947
Drug: Delayed patient-led
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed patient-led prescription strategy
Study: 17513173
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg/day until disease progression
Study: 17513173
Drug: Standard gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard gemcitabine infusion
Study: 17513173
Drug: PCI gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI gemcitabine 1200 mg/m(2) in a 120-min infusion
Study: 10452209
Drug: Three telephone
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three telephone calls and oral and written self-care measures for specific side effects
Study: 10452209
Drug: Higher ESCA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher ESCA scores before chemotherapy
Study: 10452209
Drug: Telephone call
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone call and written self-care measures after the second, third, and fourth chemotherapy treatments
Study: 2180341
Drug: Intravenous ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketanserin (0.14 mg/kg)
Study: 29085387
Drug: TCMS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCMS plus PEDT combination therapy
Study: 29085387
Drug: TCMS monotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCMS monotherapy
Study: 29085387
Drug: PEDT monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEDT monotherapy
Study: 21792758
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with combined preoperative intraarterial infusion and intravenous chemotherapy before gastrectomy and D2 lymphadenectomy
Study: 17257877
Drug: Nasal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal vaccine candidate (50 microg HBsAg and 50 microg HBcAg)
Study: 17257877
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% physiologic saline solution)
Study: 14665895
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto (325 mg daily)
Study: 11695935
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 microg, twice daily for 12 months)
Study: 11695935
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 microg, twice daily for 12 months)
Study: 8615323
Drug: ACEI (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (5 mg ramipril)
Study: 21154265
Drug: Citrulline malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline malate (3 g/day)
Study: 7883113
Drug: Regular beef/pork
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular beef/pork insulin
Study: 2168836
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (0.4 mg i.v.)
Study: 31488484
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual as provided by their general practitioner
Study: 23627714
Drug: Static magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static magnetic field (SMF) exposure for 30 minutes, 10 weekly visits; 192 millitesla peak‐to‐peak value
Study: 23627714
Drug: Non‐magnetized pads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐magnetized pads (sham) for 30 minutes, 10 weekly visits
Study: 21823377
Drug: Epidural levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural levobupivacaine (15 ml of 0.5%)
Study: 20368213
Drug: muraglitazar (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: muraglitazar (0.5, 1.5, 5, 10, and 20 mg)
Study: 20368213
Drug: pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (15 mg)
Study: 17111783
Drug: Ribavirin plus
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin plus IFN alpha‐2b 5 MU/day for 1 month followed by IFN alpha‐2b 5 MU thrice weekly for 5 months (Group A)
Study: 17111783
Drug: Ribavirin plus
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin plus IFN alpha‐2b 5 MU thrice weekly for 6 months (Group B)
Study: 17111783
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (Group A)
Study: 11727875
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (plano lens training)
Study: 7956629
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) insulin infusion via programmable implantable pumps
Study: 7956629
Drug: Multiple subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple subcutaneous (SC) injections
Study: 21234629
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment combining cognitive behavioural therapy (CBT), graded exercise therapy (GET), and pharmacological treatment
Study: 21234629
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (exercise counselling and pharmacological treatment)
Study: 8976803
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy plus calcium (Prempak C or Premarin 0.625 mg with 1 g calcium daily)
Study: 8976803
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (1 g calcium daily)
Study: 1309303
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) administered at 75 mg/m2 in 3-week cycles
Study: 1309303
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) total dose of 450 mg/m2 across all groups
Study: 1309303
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) administration
Study: 29667066
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg
Study: 29667066
Drug: Cabozantinib 20
Normalized name: cabozantinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 20 mg
Study: 25773465
Drug: 4.6% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.6% menthol gel
Study: 25773465
Drug: 10.0% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0% menthol gel
Study: 17033530
Drug: 25 to
Normalized name: Hydrasyn25 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 to 75 g/day milk-based fortified spreads
Study: 17033530
Drug: Unsupplemented controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupplemented controls (0 to 5 g FS)
Study: 10710119
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg/day) + Bezafibrate (400 mg/day)
Study: 9094876
Drug: High glycogen
Normalized name: glycogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glycogen (HG) treatment
Study: 9094876
Drug: Low glycogen
Normalized name: glycogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycogen (LG) treatment
Study: 23718572
Drug: 4 g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of FIB
Study: 22854310
Drug: Baclofen (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (titrated up to 60 mg daily or maximum tolerated dose, 48 days)
Study: 20044530
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril plus indapamide for those without contraindications)
Study: 17594201
Drug: garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: garenoxacin 600 mg administered alone
Study: 17594201
Drug: garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: garenoxacin 600 mg with Al-Mg antacid
Study: 17594201
Drug: garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: garenoxacin 600 mg administered 2 hours after Al-Mg antacid
Study: 17594201
Drug: garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: garenoxacin 600 mg administered 4 hours after Al-Mg antacid
Study: 17594201
Drug: garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: garenoxacin 600 mg administered 4 hours before Al-Mg antacid
Study: 17594201
Drug: garenoxacin 600
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: garenoxacin 600 mg administered 2 hours before Al-Mg antacid
Study: 16170978
Drug: Oral-B Indicator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B Indicator manual toothbrush
Study: 11094553
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (PTCA or CABG)
Study: 8497491
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil concentrate (FOC) capsules (15 x 1 g/d)
Study: 8497491
Drug: Placebo (PO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PO) capsules (15 x 1 g/d)
Study: 28884969
Drug: New procaterol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New procaterol dry powder inhaler (20 μg)
Study: 28884969
Drug: Approved procaterol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approved procaterol dry powder inhaler (20 μg)
Study: 27443162
Drug: Mixed model
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed model of dose estimates based on current and prior INRs
Study: 18473867
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus a provisional GP IIb/IIIa inhibitor
Study: 16433897
Drug: Intravenous heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heroin administration (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Study: 16433897
Drug: Heroin inhalation
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin inhalation (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Study: 10674593
Drug: Meclizine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclizine (50 mg pretreatment)
Study: 10674593
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (no pretreatment)
Study: 2821397
Drug: Intravenous CMV
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CMV immune globulin
Study: 27522394
Drug: Once-daily fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fixed combination (ODFC) of perindopril 10mg, indapamide 2.5mg, amlodipine 5 or 10mg, and atorvastatin 20mg
Study: 27522394
Drug: Free-drug combination
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-drug combination (FDC) of the 3 antihypertensive agents plus atorvastatin 20mg
Study: 20964767
Drug: 0.5 ml·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml·kg(‐1) of local anesthetic solution
Study: 20964767
Drug: 0.75 ml·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml·kg(‐1) of local anesthetic solution
Study: 20964767
Drug: 1.0 ml·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml·kg(‐1) of local anesthetic solution
Study: 21679304
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg (titrated to 20 or 5 mg after 4 weeks)
Study: 8039534
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg capsule) after a full meal
Study: 8039534
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg capsule) after a full meal
Study: 8039534
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg capsule) on an empty stomach
Study: 8039534
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg capsule) after a light meal
Study: 8039534
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg capsule) on an empty stomach
Study: 8039534
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg capsule) after a light meal
Study: 3043994
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg b.i.d.
Study: 30115530
Drug: Topical pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical pirfenidone